GT Biopharma Statistics
Total Valuation
GT Biopharma has a market cap or net worth of $15.84 million. The enterprise value is $7.73 million.
Important Dates
The last earnings date was Friday, May 15, 2026, before market open.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GT Biopharma has 36.06 million shares outstanding. The number of shares has increased by 484.42% in one year.
| Current Share Class | 36.06M |
| Shares Outstanding | 36.06M |
| Shares Change (YoY) | +484.42% |
| Shares Change (QoQ) | +133.34% |
| Owned by Insiders (%) | 7.02% |
| Owned by Institutions (%) | 6.05% |
| Float | 33.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.17 |
| P/TBV Ratio | 2.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.14
| Current Ratio | 4.14 |
| Quick Ratio | 3.69 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -70.20 |
Financial Efficiency
Return on equity (ROE) is -921.55% and return on invested capital (ROIC) is -252.61%.
| Return on Equity (ROE) | -921.55% |
| Return on Assets (ROA) | -131.76% |
| Return on Invested Capital (ROIC) | -252.61% |
| Return on Capital Employed (ROCE) | -175.96% |
| Weighted Average Cost of Capital (WACC) | 8.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$37.04M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.79% in the last 52 weeks. The beta is 0.86, so GT Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -83.79% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.62 |
| Relative Strength Index (RSI) | 54.20 |
| Average Volume (20 Days) | 2,336,775 |
Short Selling Information
The latest short interest is 2.08 million, so 5.75% of the outstanding shares have been sold short.
| Short Interest | 2.08M |
| Short Previous Month | 604,557 |
| Short % of Shares Out | 5.75% |
| Short % of Float | 6.25% |
| Short Ratio (days to cover) | 1.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.34M |
| Pretax Income | -30.41M |
| Net Income | -37.04M |
| EBITDA | n/a |
| EBIT | -13.34M |
| Earnings Per Share (EPS) | -$2.96 |
Full Income StatementBalance Sheet
The company has $8.92 million in cash and n/a in debt, with a net cash position of $8.92 million or $0.25 per share.
| Cash & Cash Equivalents | 8.92M |
| Total Debt | n/a |
| Net Cash | 8.92M |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | 7.58M |
| Book Value Per Share | 0.22 |
| Working Capital | 7.58M |
Full Balance SheetCash Flow
| Operating Cash Flow | -13.18M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -13.18M |
| FCF Per Share | -$0.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
